PA HB2267

Secondary school students with cystic fibrosis or pancreatic insufficiency may possess and self-administer prescribed pancreatic enzyme replacement therapy (PERT) at school, provided parents submit a health care practitioner's written order, parental request relieving the school of liability, and written acknowledgments from both the school nurse and student.

School entities must adopt written policies allowing PERT possession and self-administration, including procedures for documentation submission, designated storage locations, and limits on quantities brought to school (daily supply only).

Schools may revoke a student's self-carry privilege if the student fails to comply with school rules, their service agreement or IEP, or demonstrates inability to safeguard PERT from other students.

When self-carry privileges are revoked, schools must store PERT in a readily accessible location and notify the school nurse and other designated employees of its location.

Applies to all school districts, intermediate units, career and technical schools, charter schools, cyber charter schools, and regional charter schools, taking effect 60 days after enactment.